PET imaging of tau pathology in Alzheimer disease may benefit from the use of white matter
reference regions. These regions have shown reduced variability compared with …

PET amyloid imaging is increasingly used in research trials related to Alzheimer disease
and has potential as a quantitative biomarker. This study had 3 objectives: first, to describe a …

The accurate measurement of β-amyloid (Aβ) change using amyloid PET imaging is
important for Alzheimer disease research and clinical trials but poses several unique …

In this article, we describe an image analysis strategy with improved power for tracking
longitudinal amyloid-β (Aβ) PET changes and evaluating Aβ-modifying treatments. Methods …

Introduction Relying on magnetic resonance imaging (MRI) for quantification of positron
emission tomography (PET) images may limit generalizability of the results. We evaluated …

Amyloid positron-emission-tomography (PET) offers an important research and diagnostic
tool for investigating Alzheimer's disease (AD). The majority of amyloid PET studies have …

Purpose Alzheimer's disease (AD) is the most common form of dementia. Clinically, it is
characterized by progressive cognitive and functional impairment with structural hallmarks of …

Amyloid-β deposition into plaques is a pathologic hallmark of Alzheimer disease appearing
years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a …

Objectives Quantification of tau accumulation using positron emission tomography (PET) is
critical for the diagnosis of Alzheimer's disease (AD). This study aimed to evaluate the …

Alzheimer disease (AD) is characterized by β-amyloid (Aβ) plaques and tau neurofibrillary
tangles. There are several PET imaging biomarkers for Aβ including 11C-PiB and 18F …